—
C+
C+ The full Closelooknet — membership. Open the C+ overview

PharmaEssentia (6446.TW) — chart, structure and Closelooknet read

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for 6446.TW, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 61/100 · S&P 500 fund at 75, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-10-06
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 98th percentile of the window, +5.7% over 20 sessions. Factor regime → 2026-10-06
  • Sovereign pressure Index 0.74 · up 0.17 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-06

Company snapshot — PharmaEssentia

6446.TW in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
PharmaEssentia is a biopharmaceutical company that researches and develops specialty drugs, reagents and active pharmaceutical ingredients. Its main product, BESREMi, is an interferon therapy used to treat certain blood disorders, including polycythemia vera. It also develops several experimental treatments for cancer and immune conditions, and sells across Asia, Europe and the Americas. The company is headquartered in Taipei, Taiwan.
Where it sits in the stack
PharmaEssentia has no seat in our index; it belongs to the Healthcare sleeve of our universe, within drug manufacturers focused on specialty and generic medicines, outside the AI build-out stack we track under Rubin or Halo.
Who it is priced against
The diary has no peer group listed for this name. A comparison the market sometimes draws is with Bristol Myers Squibb, which also develops therapies for blood disorders.
Why Closelooknet tracks it
PharmaEssentia carries no index seat and no Closelooknet score has been built for it yet; the diary has not quoted this name in any edition so far.
What the diary watches
The diary watches whether new approvals or wider adoption of its interferon therapy change the company's revenue mix beyond its current product line.

PharmaEssentia (6446.TW) trades on the TW exchange in Taiwan.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 21.78%, semi-annual · last 124 TWD on 2026-07-06

Dividends and capital return

What 6446.TW pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 256 TWD per share · a 21.78% yield on the 2026-10-06 close 2 distributions, paid twice a year 2026-10-06
  • Change on the year +370.2% against the prior twelve months prior twelve months 54.42 TWD per share
  • Last distribution 124 TWD per share as the price series records it, within days of the ex-date 2026-07-06
  • By calendar year 2025: 54.42 TWD (partial) · 2026: 256 TWD to date first distribution recorded in the three-year window: 2025-08-11

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-10-07

Quick answers

What is PharmaEssentia (6446.TW)?

PharmaEssentia trades as 6446.TW on the TW exchange (Taiwan) in the Closelooknet research universe, as of the registry build of 2026-10-07.

Is 6446.TW in a Closelooknet index?

Not currently — PharmaEssentia is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-10-07.

Where does 6446.TW trade against its moving averages?

Pullback inside an uptrend stack: Trades -9.1% vs the 50-day and +30.4% vs the 200-day average, 28.6% below the 52-week high and +159.7% off the 52-week low. Computed from daily closes. As of 2026-10-06 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

What does PharmaEssentia do?

PharmaEssentia is a biopharmaceutical company that researches and develops specialty drugs, reagents and active pharmaceutical ingredients. Its main product, BESREMi, is an interferon therapy used to treat certain blood disorders, including polycythemia vera. It also develops several experimental treatments for cancer and immune conditions, and sells across Asia, Europe and the Americas. The diary has no peer group listed for this name. A comparison the market sometimes draws is with Bristol Myers Squibb, which also develops therapies for blood disorders.

Where does PharmaEssentia sit in the AI build-out?

PharmaEssentia has no seat in our index; it belongs to the Healthcare sleeve of our universe, within drug manufacturers focused on specialty and generic medicines, outside the AI build-out stack we track under Rubin or Halo. PharmaEssentia carries no index seat and no Closelooknet score has been built for it yet; the diary has not quoted this name in any edition so far.

Does PharmaEssentia pay a dividend?

PharmaEssentia has paid 256 TWD per share over the last twelve months, paid twice a year, a trailing yield of 21.78% on the 2026-10-06 close; the last distribution recorded in the price series was 124 TWD on 2026-07-06. The "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for 6446.TW, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.